Biological monitoring of IFN-β therapy in Multiple Sclerosis

Interferon beta (IFN-β) is the most commonly prescribed disease-modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS). IFN-β therapy reduces the annual relapse rate and the lesion load measured by MRI, brain atrophy and disability progression [1,2]. Unfortunately, most patients are non-responders to treatment [3]. As MS is a heterogeneous disease, all the approved DMTs are only partially active and a variable percentage of patients are non-responders. Non-responsive patients can be divided into two subgroups: pathogenesis-related non-responders and immuno-pharmacological non-responders.

Source: Cytokine and Growth Factor Reviews - December 23, 2014 Category: Molecular Biology Authors: A. Bertolotto, L. Granieri, F. Marnetto, P. Valentino, A. Sala, M. Capobianco, S. Malucchi, A. Di Sapio, M. Malentacchi, M. Matta, M. Caldano Source Type: research